Cancer Family
Esophageal Neoplasm
CI-CAN-00000174Explore in graph →
Non-malignant555 active trials6 approved drugs12 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000174Explore in graph →
Clinical trials
2,208 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05426850 | ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma | unknown | — | 100 | Fudan UniversityOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05213312 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | unknown | Phase 2 / Phase 3 | 90 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04215471 | NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma(NATION1907II) | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03623737 | Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC | unknown | Phase 2 / Phase 3 | 248 | National Taiwan University HospitalOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT05199168 | Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves During Thoracoscopic Esophagectomy | unknown | N/A | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05394415 | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC(LATE) | unknown | Phase 1 / Phase 2 | 30 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05381636 | Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical Study | unknown | Phase 2 | 120 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 19, 2022 | clinicaltrials |
| NCT04460066 | A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. | unknown | Phase 1 / Phase 2 | 70 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT05342805 | Comparison of Subtotal Stomach and Narrow Gastric Tube After Esophagectomy | unknown | N/A | 50 | University Medical Center Ho Chi Minh City (UMC)OTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05349045 | Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer(AIPAAIAEC) | unknown | — | 300 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05074914 | Unintentional Weight Loss After Oesophagectomy(UWL) | unknown | N/A | 64 | University College DublinOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05322499 | Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer | unknown | Phase 2 | 80 | Zhejiang Cancer HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05317325 | A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05287880 | Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC | unknown | — | 60 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Mar 18, 2022 | clinicaltrials |
| NCT04390958 | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 70 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT04825470 | Liver Transplantation for Unresectable GIST Liver Metastases(TRANSGIST) | unknown | N/A | 50 | Hospital Universitario Virgen de la ArrixacaOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT03917966 | The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC | unknown | Phase 2 | 80 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05265962 | Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade | unknown | Phase 2 | 85 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Mar 4, 2022 | clinicaltrials |
| NCT02970539 | Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers | unknown | Phase 1 | 36 | Athenex, Inc.INDUSTRY | 2 | Feb 16, 2022 | clinicaltrials |
| NCT04177797 | Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT04390945 | Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer | unknown | Phase 2 | 62 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT05208775 | A Comparative Study of Endoscopic Submucosal Dissection and Photodynamic Therapy for Early Esophageal Cancer | unknown | N/A | 46 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 0 | Jan 26, 2022 | clinicaltrials |
| NCT04615806 | The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy | unknown | N/A | 40 | Fujian Medical University Union HospitalOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05199649 | Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora | unknown | N/A | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT03140189 | Robot-assisted IVOR-LEWIS Esophagectomy(RAILE) | unknown | — | 51 | Ruijin HospitalOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05183958 | A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer | unknown | Phase 2 | 118 | Zhejiang Cancer HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05174117 | Influence of Different Light Dose on the Adverse Effect of Swallowing for Esophageal Carcinoma | unknown | N/A | 57 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT05174325 | Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT05007145 | PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma(REVO) | unknown | Phase 2 | 92 | Fujian Cancer HospitalOTHER_GOV | 1 | Dec 21, 2021 | clinicaltrials |
| NCT04506138 | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 46 | Zhejiang Cancer HospitalOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT04286958 | A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC(ESCC) | unknown | Phase 2 | 40 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT05130684 | Neo-NTP-CRT for Locally Advanced ESCC(Neo-NTP-CRT) | unknown | Phase 2 | 43 | National Taiwan University HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT02749513 | Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients | unknown | Early Phase 1 | 18 | Dallas VA Medical CenterFED | 1 | Nov 4, 2021 | clinicaltrials |
| NCT05103501 | Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy(SINCERE) | unknown | Phase 2 | 54 | Shanghai Chest HospitalOTHER | 0 | Nov 2, 2021 | clinicaltrials |
| NCT05067153 | Thromboprophylaxis in Oesophageal Cancer Patients(TOP-RCT) | unknown | Phase 4 | 100 | University of AarhusOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04581005 | Prehabilitation in Esophageal Cancer Care | unknown | N/A | 54 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT05049681 | Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell | unknown | Phase 3 | 234 | Feng WangOTHER | 0 | Sep 20, 2021 | clinicaltrials |
| NCT04426955 | Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT05044728 | Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | unknown | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03800953 | The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 26 | National Taiwan University HospitalOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT03387904 | Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 120 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT04622098 | Prevalence of Sub-epithelial Lesions Among Patients Undergoing EGDs in Egypt | unknown | — | 2,000 | Kafrelsheikh UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04514835 | A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC | unknown | Phase 2 | 44 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04063683 | Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC). | unknown | Phase 2 | 47 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04533490 | A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 42 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Aug 23, 2021 | clinicaltrials |
| NCT04654403 | Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer | unknown | N/A | 337 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT04888403 | Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 45 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT05013697 | TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer. | unknown | Phase 2 | 48 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 19, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 22, 2022source: clinicaltrials